Kaskela Law LLC: Shareholder Class Action Filed Against Solid Biosciences, Inc. - SLDB

RADNOR, Pa., May 06, 2018 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Solid Biosciences, Inc. (NASDAQ:SLDB) (“Solid Biosciences” or the “Company”) on behalf of purchasers of the Company’s securities between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).

Solid Biosciences investors are encouraged to visit www.kaskelalaw.com/case/solid-biosciences-inc/ to receive additional information about this action and submit their information online.  Investors may also contact attorney D. Seamus Kaskela at (888) 715 – 1740, or via email at [email protected], to discuss their legal rights and options with respect to this action.

On or around January 25, 2018, Solid Biosciences completed an initial public offering (“IPO”) of its common stock, selling 7,000,000 shares of stock to investors at $16.00 per share.

On March 14, 2018, Solid Biosciences disclosed that the U.S. Food and Drug Administration had placed a clinical hold on its SGT-001 Phase I/II clinical trial, IGNITE DMD.  Following this news, shares of Solid Biosciences’ common stock fell $16.99 per share, or over 60%, to close on March 15, 2018 at $9.32.

The shareholder class action complaint alleges that Solid Biosciences and certain of its executive officers made a series of false and misleading statements and/or failed to disclose to investors that: (i) Solid Biosciences’ lead drug candidate, SGT-001, had a high likelihood of causing adverse events in patients; and (ii) Solid Biosciences had misled investors regarding the toxicity of SGT-001.  The complaint further alleges that, as a result of the foregoing, investors purchased Solid Biosciences’ common stock at artificially inflated prices during the Class Period and sustained significant investment losses when the truth was revealed.

Investors who purchased Solid Biosciences securities during the Class Period may, no later than May 28, 2018, seek to be appointed as a lead plaintiff representative of the class through Kaskela Law or other counsel, or may choose to do nothing and remain an absent class member.  In order to be appointed as a lead plaintiff a class member must meet certain legal requirements. 

Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors.  For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(888) 715 – 1740
[email protected]
www.kaskelalaw.com